Xiaojie Lu

List of Publications by Year in Descending Order

63 papers	1,617 citations	21 h-index	38 g-index
72 ext. papers	2,138 ext. citations	6.5 avg, IF	5.28 L-index

#	Paper	IF	Citations
63	Functional tissue-engineered bone-like graft made of a fibrin scaffold and TG2 gene-modified EMSCs for bone defect repair. *NPG Asia Materials*, **2021**, 13,	10.3	14
62	Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy. *British Journal of Pharmacology*, **2021**, 178, 2651-2670	8.6	3
61	Circular RNA Circ0021205 Promotes Cholangiocarcinoma Progression Through MiR-204-5p/RAB22A Axis. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 653207	5.7	4
60	Placental Immune Tolerance and Organ Transplantation: Underlying Interconnections and Clinical Implications. *Frontiers in Immunology*, **2021**, 12, 705950	8.4	0
59	Management of patients with intermediate stage hepatocellular carcinoma. *Therapeutic Advances in Medical Oncology*, **2020**, 12, 1758835920970840	5.4	9
58	Hsa_circ_0070963 inhibits liver fibrosis via regulation of miR-223-3p and LEMD3. *Aging*, **2020**, 12, 1643-1655	5.6	13
57	Gut microbiome and cancer immunotherapy. *Journal of Cellular Physiology*, **2020**, 235, 4082-4088	7	20
56	FibroBox: a novel noninvasive tool for predicting significant liver fibrosis and cirrhosis in HBV infected patients. *Biomarker Research*, **2020**, 8, 48	8	4
55	The LGMN pseudogene promotes tumor progression by acting as a miR-495-3p sponge in glioblastoma. *Cancer Letters*, **2020**, 490, 111-123	9.9	9
54	Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. *Biomarker Research*, **2020**, 8, 35	8	41
53	Laparoscopic Microwave Ablation of Hepatocellular Carcinoma at Liver Surface: Technique Effectiveness and Long-Term Outcomes. *Technology in Cancer Research and Treatment*, **2019**, 18, 1533033818824338	2.7	7
52	Applications and advances of CRISPR-Cas9 in cancer immunotherapy. *Journal of Medical Genetics*, **2019**, 56, 4-9	5.8	27
51	Exosomes derived from exhausted CD8+ T cells impaired the anticancer function of normal CD8+ T cells. *Journal of Medical Genetics*, **2019**, 56, 29-31	5.8	29
50	Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. *Therapeutic Advances in Medical Oncology*, **2019**, 11, 1758835919862692	5.4	54
49	T Cell Dysfunction in Cancer Immunity and Immunotherapy. *Frontiers in Immunology*, **2019**, 10, 1719	8.4	121
48	The landscape of DNA methylation in hepatocellular carcinoma. *Journal of Cellular Physiology*, **2019**, 234, 2631-2638	7	7
47	Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis. *Journal of Cellular Physiology*, **2019**, 234, 1062-1070	7	18

46	Identification of LINC01615 as potential metastasis-related long noncoding RNA in hepatocellular carcinoma. *Journal of Cellular Physiology*, **2019**, 234, 12964-12970	7	9
45	Cancer immunotherapy: challenges and clinical applications. *Journal of Medical Genetics*, **2019**, 56, 1-3	5.8	15
44	Therapeutic advances for patients with intermediate hepatocellular carcinoma. *Journal of Cellular Physiology*, **2019**, 234, 12116-12121	7	20
43	Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. *Journal of Cellular Physiology*, **2019**, 234, 12122-12132	7	25
42	Identification of TAF1, HNF4A, and CALM2 as potential therapeutic target genes for liver fibrosis. *Journal of Cellular Physiology*, **2019**, 234, 9045-9051	7	15
41	Genetic and phenotypic difference in CD8 T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma. *Journal of Medical Genetics*, **2019**, 56, 18-21	5.8	20
40	14-3-3□delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T□lymphocytes. *Cell Death and Disease*, **2018**, 9, 159	9.8	59
39	T cell exhaustion in cancer: Mechanisms and clinical implications. *Journal of Cellular Biochemistry*, **2018**, 119, 4279-4286	4.7	20
38	Decreased levels of serum exosomal miR-638 predict poor prognosis in hepatocellular carcinoma. *Journal of Cellular Biochemistry*, **2018**, 119, 4711-4716	4.7	95
37	Pitfalls in the non-invasive assessment of liver fibrosis with eLIFT-FM algorithm. *Journal of Hepatology*, **2018**, 68, 602-603	13.4	
36	Study on the relationship between insulin growth factor 1 and liver fibrosis in patients with chronic hepatitis C with type 2 diabetes mellitus. *Journal of Cellular Biochemistry*, **2018**, 119, 9513-9518	4.7	5
35	Assessment of liver fibrosis with the gamma-glutamyl transpeptidase to platelet ratio: a multicentre validation in patients with HBV infection. *Gut*, **2018**, 67, 1903-1904	19.2	14
34	The long noncoding RNA NEAT1 contributes to hepatocellular carcinoma development by sponging miR-485 and enhancing the expression of the STAT3. *Journal of Cellular Physiology*, **2018**, 233, 6733-6741	7	43
33	Four differentially methylated gene pairs to predict the prognosis for early stage hepatocellular carcinoma patients. *Journal of Cellular Physiology*, **2018**, 233, 6583-6590	7	16
32	DACH1 inhibits glioma invasion and tumor growth via the Wnt/catenin pathway. *OncoTargets and Therapy*, **2018**, 11, 5853-5863	4.4	5
31	NEAT1 upregulates TGF-□1 to induce hepatocellular carcinoma progression by sponging hsa-mir-139-5p. *Journal of Cellular Physiology*, **2018**, 233, 8578-8587	7	43
30	PPAR Antagonizes Hypoxia-Induced Activation of Hepatic Stellate Cell through Cross Mediating PI3K/AKT and cGMP/PKG Signaling. *PPAR Research*, **2018**, 2018, 6970407	4.3	10
29	Lack of Aquaporin 9 Reduces Brain Angiogenesis and Exaggerates Neuronal Loss in the Hippocampus Following Intracranial Hemorrhage in Mice. *Journal of Molecular Neuroscience*, **2017**, 61, 351-358	3.3	7

28	Towards In Silico Prediction of the Immune-Checkpoint Blockade Response. *Trends in Pharmacological Sciences*, **2017**, 38, 1041-1051	13.2	10
27	Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities. *Oncotarget*, **2017**, 8, 90521-90531	3.3	62
26	The pros and cons of dying tumour cells in adaptive immune responses. *Nature Reviews Immunology* , **2017**, 17, 591	36.5	10
25	Delivery of a chemotherapeutic drug using novel hollow carbon spheres for esophageal cancer treatment. *International Journal of Nanomedicine*, **2017**, 12, 6759-6769	7.3	20
24	DDX11-AS1 as potential therapy targets for human hepatocellular carcinoma. *Oncotarget*, **2017**, 8, 44195-44202	3.3	17
23	Anticancer Opportunity Created by Loss of Tumor Suppressor Genes. *Technology in Cancer Research and Treatment*, **2016**, 15, 729-731	2.7	2
22	LINE-1 in cancer: multifaceted functions and potential clinical implications. *Genetics in Medicine*, **2016**, 18, 431-9	8.1	47
21	Safety and efficacy of TACE and gamma knife on hepatocellular carcinoma with portal vein invasion. *Gut*, **2016**, 65, 715-6	19.2	15
20	CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles. *Molecular Therapy - Nucleic Acids*, **2016**, 5, e349	10.7	92
19	CRISPR-Cas9 for medical genetic screens: applications and future perspectives. *Journal of Medical Genetics*, **2016**, 53, 91-7	5.8	30
18	New Insights into the Epithelial-to-Mesenchymal Transition in Cancer. *Trends in Pharmacological Sciences*, **2016**, 37, 246-248	13.2	25
17	Krüppel-like factor 2 promotes cell proliferation in hepatocellular carcinoma through up-regulation of c-myc. *Cancer Biology and Therapy*, **2016**, 17, 20-6	4.6	12
16	Pseudogene transcripts: Participants in tumorigenicity and promising therapeutic targets. *Leukemia Research*, **2016**, 42, 105-6	2.7	1
15	Managerial Decision-making for Daily Case Allocation Scheduling and the Impact on Perioperative Quality Assurance. *Translational Perioperative and Pain Medicine*, **2016**, 1, 20-30	1.7	3
14	Tolerability and efficacy of gamma knife radiosurgery on hepatocellular carcinoma with portal vein tumor thrombosis. *Oncotarget*, **2016**, 7, 3614-22	3.3	10
13	Oridonin, a novel lysine acetyltransferases inhibitor, inhibits proliferation and induces apoptosis in gastric cancer cells through p53- and caspase-3-mediated mechanisms. *Oncotarget*, **2016**, 7, 22623-31	3.3	45
12	Microwave ablation of hepatocellular carcinoma as first-line treatment: long term outcomes and prognostic factors in 221 patients. *Scientific Reports*, **2016**, 6, 32728	4.9	19
11	Competing endogenous RNA interplay in cancer: mechanism, methodology, and perspectives. *Tumor Biology*, **2015**, 36, 479-88	2.9	94

10	CRISPR-Cas9: a new and promising player in gene therapy. *Journal of Medical Genetics*, **2015**, 52, 289-96	5.8	115
9	Modeling cancer processes with CRISPR-Cas9. *Trends in Biotechnology*, **2015**, 33, 317-9	15.1	7
8	Pseudogene in cancer: real functions and promising signature. *Journal of Medical Genetics*, **2015**, 52, 17-24	5.8	75
7	CRISPR screen: a high-throughput approach for cancer genetic research. *Clinical Genetics*, **2015**, 88, 32-3	4	1
6	Krüppel-like factors in hepatocellular carcinoma. *Tumor Biology*, **2015**, 36, 533-41	2.9	28
5	Pseudogene: promising signature for cancer reclassification : comment on "The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes", Nat Commun. 2014; 5:3963. *Medical Oncology*, **2015**, 32, 354	3.7	1
4	Metabolomic profiling of neoplastic lesions in mice. *Methods in Enzymology*, **2014**, 543, 261-73	1.7	1
3	Identification of copy number variation-driven genes for liver cancer via bioinformatics analysis. *Oncology Reports*, **2014**, 32, 1845-52	3.5	11
2	CE-MS based on moving reaction boundary method for urinary metabolomic analysis of gastric cancer patients. *Electrophoresis*, **2014**, 35, 1032-9	3.6	28
1	Krüppel-like factor 2 promotes liver steatosis through upregulation of CD36. *Journal of Lipid Research*, **2014**, 55, 32-40	6.3	19